|
|
|
Thursday, August 07, 2008
The FDA's Black Box
A new anesthesia drug was supposed to be the gem in Schering-Plough's $14 billion purchase of rival Organon. Schering CEO Fred Hassan told analysts he expected the medicine, used to quickly reverse other drugs that cause paralysis, to "transform anesthesia."
Please click here for more details.
|
|
